sintilimab Archives -

FDA advisors have voted against approval of Eli Lilly and Innovent Biologics’ cancer immunotherapy sintilimab, undermining hopes of

Unswayed by a discount pledge, FDA adcomm rejects Lilly’s PD-1 drug

https://pharmaphorum.com/news/unswayed-by-lillys-discount-pledge-fda-adcomm-rejects-its-pd-1-drug/

The FDA has dropped a bomb on Eli Lilly’s marketing application for cancer immunotherapy sintilimab ahead of an

FDA won’t back Lilly’s PD-1 antibody based on Chinese data alone

https://pharmaphorum.com/news/fda-wont-review-lillys-pd-1-antibody-based-on-chinese-data-alone/

Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent’s

Good news for Lilly as sintilimab hits the spot in lung cancer again

https://pharmaphorum.com/news/good-news-for-lilly-as-sintilimab-hits-the-spot-in-lung-cancer-again/

The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected

FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option

https://pharmaphorum.com/news/fda-review-of-lilly-innovents-sintilimab-paves-way-for-cut-price-immunotherapy-option/

sintilimab